Streetbeat News

Revenues

OSIS

OSI Systems has secured a $42 million contract from an international airport to provide checkpoint and hold baggage screening solutions.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:42 pm

RNXT

RenovoRx's CEO updated shareholders on the company's progress in Q1 2024, highlighting significant milestones, including $17.2 million raised, advancements in the Phase III TIGeR-PaC clinical trial, and the expansion of their TAMP therapy platform. Key management promotions and supportive research publications were also noted.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:42 pm

TAOP

Taoping Inc. has signed a $1 million contract for smart terminals and entered a strategic cooperation agreement with Zhenjiang Fengchao Information Technology.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:42 pm

STSS

Sharps Technology shares are trading higher after the company signed a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:41 pm

FXI

TSLA

Tesla is making a significant push to roll out its advanced Full Self-Driving (FSD) technology in China. This move is part of Tesla's broader strategy to expand its market share in the world's largest auto market. The company aims to introduce the FSD feature to Chinese consumers, which could potentially boost its sales and market presence in the region.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:41 pm

BBW

BFOR

Build-A-Bear Workshop, Inc. (NYSE: BBW) shares are plunging premarket after missing Q1 earnings expectations and reporting lower sales. Revenue totaled $114.7 million, missing the consensus of $120.6 million, and EPS of $0.82 missed the expected $1.03. Sales decreased 4.4% Y/Y, and e-commerce demand fell 11.3% Y/Y. The company reaffirmed its FY24 outlook for revenue and pre-tax income growth. BBW shares are down 17.19% premarket.

Portfolio Pulse from Lekha Gupta

May 30, 2024 | 12:40 pm

STSS

Sharps Technology has signed a 5-year, $200 million syringe sales agreement with Nephron Pharmaceuticals. This deal is expected to significantly boost Sharps Technology's revenue and market presence.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:40 pm

DG

Dollar General Corp (NYSE:DG) shares are trading higher after reporting better-than-expected first-quarter FY24 earnings. The company saw a 6% sales growth year-on-year to $9.910 billion, beating the analyst consensus estimate. Same-store sales increased by 2.4%, driven by higher customer traffic. Despite a decrease in gross profit margin and operating income, the company reported an EPS of $1.65, surpassing the consensus estimate. Dollar General reaffirmed its FY24 sales growth outlook and announced a quarterly cash dividend.

Portfolio Pulse from Shivani Kumaresan

May 30, 2024 | 12:36 pm

KSS

Kohl's Corp (NYSE:KSS) reported disappointing Q1 FY24 earnings, missing revenue and profit estimates, and slashed its FY24 outlook. The company's stock tumbled 22.6% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

May 30, 2024 | 12:33 pm

DAWN

VIRX

Day One Biopharmaceuticals (DAWN) announced the sale of a Priority Review Voucher (PRV) for $108 million. As part of the transaction, $8.1 million will be paid to Viracta Therapeutics (VIRX) to satisfy PRV-related obligations under a license agreement.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:32 pm